Major U.S. Obesity Societies Issue New Evidence-Based Guidance on Weight Loss Medications
TOS, OMA, and OAC jointly released updated pharmacological management guidance for obesity using the GRADE framework, addressing barriers to treatment access.
Quick Facts
What This Study Found
Joint expert guidance from three major U.S. obesity organizations provides updated, evidence-graded recommendations for pharmacological obesity management.
Key Numbers
How They Did This
Expert guidance statement using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to systematically evaluate evidence for obesity medications.
Why This Research Matters
Despite effective medications being available, obesity remains undertreated due to stigma, lack of insurance coverage, and limited clinician training. Updated guidance from leading societies can help standardize care.
The Bigger Picture
This guidance represents a shift toward treating obesity as a chronic disease deserving the same evidence-based pharmacological approach as diabetes or hypertension.
What This Study Doesn't Tell Us
Guidance statement rather than systematic review; GRADE assessments depend on available trial data which may not capture long-term outcomes.
Questions This Raises
- ?Will this guidance influence insurance coverage policies for obesity medications?
- ?How will these recommendations be implemented in primary care settings with limited obesity medicine training?
Trust & Context
- Key Stat:
- 40%+ of U.S. adults Obesity prevalence continues rising with severe obesity increasing fastest
- Evidence Grade:
- Expert guidance using GRADE framework — systematic evaluation of evidence quality, but recommendations reflect expert interpretation of available data.
- Study Age:
- Published 2026 in Obesity. Reflects the most current FDA-approved obesity pharmacotherapies.
- Original Title:
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.
- Published In:
- Obesity (Silver Spring, Md.) (2026)
- Authors:
- Alexander, Lydia, Purnell, Jonathan Q(2), Burridge, Karlijn, Cornier, Marc-André, Golden, Angela, Bade, Deborah, Look, Michelle, Nadglowski, Joe, Ávila-Oliver, Camila, Novillo, Francisco, Rojas-Gómez, Ana María, Hussey, Brad, Salas, Ximena Ramos
- Database ID:
- RPEP-14739
Evidence Hierarchy
Frequently Asked Questions
What is the GRADE approach?
GRADE is a systematic framework used to evaluate the quality of evidence and strength of recommendations in clinical guidelines, helping ensure guidance is based on the best available science.
Why is obesity still undertreated if medications exist?
Barriers include limited insurance coverage, weight stigma, insufficient clinician training in obesity medicine, and socioeconomic disparities in healthcare access.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14739APA
Alexander, Lydia; Purnell, Jonathan Q; Burridge, Karlijn; Cornier, Marc-André; Golden, Angela; Bade, Deborah; Look, Michelle; Nadglowski, Joe; Ávila-Oliver, Camila; Novillo, Francisco; Rojas-Gómez, Ana María; Hussey, Brad; Salas, Ximena Ramos. (2026). Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.. Obesity (Silver Spring, Md.). https://doi.org/10.1002/oby.70164
MLA
Alexander, Lydia, et al. "Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.." Obesity (Silver Spring, 2026. https://doi.org/10.1002/oby.70164
RethinkPeptides
RethinkPeptides Research Database. "Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacol..." RPEP-14739. Retrieved from https://rethinkpeptides.com/research/alexander-2026-joint-tosomaoac-expert-guidance
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.